BLAINTRAVENOUSVIALPriority Review
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
AVASTIN (bevacizumab) by Roche is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2004.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVASTIN (bevacizumab) is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis across multiple cancer indications. Administered intravenously, it works by preventing new blood vessel formation that tumors require for growth. The drug was first approved in 2004 and remains a foundational anti-angiogenic therapy.
$0.012BPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with 30% competitive pressure signals contraction; teams are likely focused on lifecycle management and transition planning rather than expansion.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
Started Dec 2027
100 enrolled
Metastatic Colorectal Cancer
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
Started Dec 2026
590 enrolled
Ovarian Cancer
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
Started Dec 2026
10 enrolled
GBM
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Started Oct 2026
600 enrolled
Colorectal Cancer
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Started Oct 2026
646 enrolled
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Worked on AVASTIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.